IZBA
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
May 2014
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
IZBA is a small-molecule ophthalmic solution approved by FDA in May 2014 for eye-related indications. The exact therapeutic mechanism and indication remain undisclosed in available data, but the formulation-focused patent portfolio suggests a novel delivery or stabilization approach. This Novartis product operates in the ophthalmology space as a topical eye drop.
Peak2.9 years to LOE
Peak lifecycle stage indicates mature sales infrastructure and stable brand team, but high competitive pressure (8/10) suggests defensive positioning and possible headcount optimization planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on IZBA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.